Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

Abstract Background The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically. Methods We invited a group of ex...

Full description

Bibliographic Details
Main Authors: Louis M. Guzzi, Tobias Bergler, Brian Binnall, Daniel T. Engelman, Lui Forni, Michael J. Germain, Eric Gluck, Ivan Göcze, Michael Joannidis, Jay L. Koyner, V. Seenu Reddy, Thomas Rimmelé, Claudio Ronco, Julien Textoris, Alexander Zarbock, John A. Kellum
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Critical Care
Subjects:
Biomarker testing
Acute kidney injury
Critical care
Expert panel
Protocols
Clinical guidelines
Online Access:http://link.springer.com/article/10.1186/s13054-019-2504-8

Internet

http://link.springer.com/article/10.1186/s13054-019-2504-8

Similar Items